Latest Breaking News On - Matthew szot - Page 1 : comparemela.com

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Matthew szotRobert blumPrnewswire cadrenal therapeutics incCadrenal therapeutics incLytham partnersVirtual healthcare equity conferenceNoble capital marketsInvestor relationsVitamink antagonist

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

/PRNewswire/ Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible.

Robert blumMatthew szotPrnewswire cadrenal therapeutics incCadrenal therapeutics incLytham partnersVirtual healthcare equity conferenceNoble capital marketsInvestor relationsVitamink antagonist

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

PONTE VEDRA, Fla., Feb. 8, 2024 /PRNewswire/ Cadrenal Therapeutics, Inc. , a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist for unmet needs in anticoagulation .

United statesJeff coleMatthew szotEspero biopharmaRobert blumQuang phamLytham partnersCadrenal therapeutics incUniversity of michiganBausch health companiesUniversity of southern californiaCompany annual report on formLegacy pharmaceuticalsPrnewswire cadrenal therapeutics incValeant pharmaceuticals internationalCorporate development

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

PONTE VEDRA, Fla., Jan. 24, 2024 /PRNewswire/ Cadrenal Therapeutics, Inc., , a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant designed to.

Douglas losordoRobert blumMatthew szotJoe pantginisPrnewswire cadrenal therapeutics incCadrenal therapeutics incCompany webcastHc wainwright coLytham partnersChief medical officerManaging directorVitamink antagonist

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J P Morgan Annual Healthcare Conference

PONTE VEDRA, Fla., Jan. 4, 2024 /PRNewswire/ Cadrenal Therapeutics, Inc., , a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant designed to.

San franciscoUnited statesRobert blumMatthew szotQuang phamLytham partnersHilton san francisco union squareCompany annual report on formPrnewswire cadrenal therapeutics incNasdaq entrepreneurial centerCadrenal therapeutics incBiotech showcaseAnnual healthcareYosemitec roomFast trackEnd stage kidney disease